An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation

Trial Profile

An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Tavokinogene telsaplasmid (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2017 Planned number of patients changed from 41 to 42.
    • 19 Oct 2017 According to an OncoSec Medical media release, data from the study were presented in an oral presentation at the 2017 9th World Congress of Melanoma-A Joint Meeting with the Society for Melanoma Research.
    • 19 Oct 2017 Results presented in an OncoSec Medical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top